Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02345772 · ClinicalTrials.gov registry record · Phase 1
Neoadjuvant Hormonal Therapy Combined With Chemoimmunotherapy
A Phase 1 study, sponsored by Western Regional Medical Center.
- Terminated
- Registry status
- Phase 1
- Development phase
- 4
- Enrollment target
NCT02345772: Clinical Trial Phase 1 study, sponsored by Western Regional Medical Center.
NCT02345772 is a Phase 1 study that was terminated before completion, run by Western Regional Medical Center. The registered enrollment target is 4 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02345772, a Phase 1 study, was terminated before completion, sponsored by Western Regional Medical Center.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 4 participants
- Enrollment target
Study Summary
Hormonal therapy administered before surgery in ER-positive and HER2-positive patients with breast cancer.
Interventions
- DRUG Docetaxel
- DRUG fulvestrant 500 mg
- DRUG Trastuzumab (H, 8mg/kg
- DRUG Pertuzumab (P, 840 mg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 4 participants |
| Start Date | 2014-07 |
| Est. Completion | 2015-11 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02345772
The ClinicalTrials.gov registry entry for NCT02345772 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 4 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Western Regional Medical Center, which has 17 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Docetaxel is the first listed.
NCT02345772 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02345772 about?
NCT02345772 is a clinical study titled "Neoadjuvant Hormonal Therapy Combined With Chemoimmunotherapy". Hormonal therapy administered before surgery in ER-positive and HER2-positive patients with breast cancer.
What is the current status of trial NCT02345772?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 4 participants. The study started on 2014-07. Estimated completion is 2015-11.
What interventions are being tested in trial NCT02345772?
The interventions under investigation include: Docetaxel (DRUG), fulvestrant 500 mg (DRUG), Trastuzumab (H, 8mg/kg (DRUG), Pertuzumab (P, 840 mg (DRUG).
Who is sponsoring clinical trial NCT02345772?
This trial is sponsored by Western Regional Medical Center, which has 17 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.